Blueprint
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of November 2016
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X
Form
40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __ No
X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule
12g3-2(b): 82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.Total
Voting Rights dated 01st November
2016
1
November 2016
Transparency
Directive
Voting
Rights and Capital
The
following notification is made in accordance with the UK Financial
Conduct Authority's Disclosure and Transparency Rule 5.6.1. On 31
October 2016 the issued share capital of AstraZeneca PLC with
voting rights is 1,265,040,093 ordinary shares of US$0.25. No
shares are held in Treasury. Therefore, the total number of voting
rights in AstraZeneca PLC is 1,265,040,093.
The
above figure for the total number of voting rights may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, AstraZeneca PLC under the UK
Financial Conduct Authority's Disclosure and Transparency
Rules.
About
AstraZeneca
AstraZeneca is a
global, science-led biopharmaceutical company that focuses on the
discovery, development and commercialisation of prescription
medicines, primarily for the treatment of diseases in three main
therapy areas - Oncology, Cardiovascular & Metabolic Diseases
and Respiratory. The Company also is selectively active in the
areas of autoimmunity, neuroscience and infection. AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide. For more information,
please visit www.astrazeneca.com
and follow us on Twitter @AstraZeneca.
|
Media Enquiries
|
|
|
|
Neil
Burrows
|
UK/Global
|
+44 203
749 5637
|
|
Vanessa
Rhodes
|
UK/Global
|
+44 203
749 5736
|
|
Karen
Birmingham
|
UK/Global
|
+44 203
749 5634
|
|
Rob
Skelding
|
UK/Global
|
+44 203
749 5821
|
|
Jacob
Lund
|
Sweden
|
+46 8
553 260 20
|
|
Michele
Meixell
|
US
|
+1 302
885 2677
|
|
|
|
|
|
Investor Relations
|
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203
749 5712
|
|
Craig
Marks
|
Finance,
Fixed Income, M&A
|
+44
7881 615 764
|
|
Henry
Wheeler
|
Oncology
|
+44 203
749 5797
|
|
Mitchell
Chan
|
Oncology
|
+1 240
477 3771
|
|
Lindsey
Trickett
|
Cardiovascular
& Metabolic Diseases
|
+1 240
543 7970
|
|
Nick
Stone
|
Respiratory
|
+44 203
749 5716
|
|
Christer
Gruvris
|
Autoimmunity,
neuroscience & infection
|
+44 203
749 5711
|
|
US toll
free
|
|
+1 866
381 7277
|
Adrian
Kemp
Company
Secretary, AstraZeneca PLC
-ENDS-
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
AstraZeneca
PLC
|
Date:
01 November 2016
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|